BMC Cancer (Oct 2024)

The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype

  • Philipp Ziegler,
  • Andreas D. Hartkopf,
  • Markus Wallwiener,
  • Lothar Häberle,
  • Hans-Christian Kolberg,
  • Peyman Hadji,
  • Hans Tesch,
  • Johannes Ettl,
  • Diana Lüftner,
  • Volkmar Müller,
  • Laura L. Michel,
  • Erik Belleville,
  • Pauline Wimberger,
  • Carsten Hielscher,
  • Hanna Huebner,
  • Sabrina Uhrig,
  • Lena A. Wurmthaler,
  • Carolin C. Hack,
  • Christoph Mundhenke,
  • Christian Kurbacher,
  • Peter A. Fasching,
  • Rachel Wuerstlein,
  • Michael Untch,
  • Wolfgang Janni,
  • Florin-Andrei Taran,
  • Michael P. Lux,
  • Diethelm Wallwiener,
  • Sara Y. Brucker,
  • Tanja N. Fehm,
  • Andreas Schneeweiss,
  • Chloë Goossens

DOI
https://doi.org/10.1186/s12885-024-13038-3
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Although adequate physical activity has been shown to be beneficial in early breast cancer, evidence in metastatic breast cancer is sparse and contradictory, which could be related to distinct effects of physical activity on the different molecular cancer subtypes. Therefore, we here evaluated the effect of physical activity on progression-free and overall survival (PFS, OS) in metastatic breast cancer, specifically looking at molecular subtypes. Methods International Physical Activity Questionnaire (IPAQ) questionnaires, filled out by patients enrolled in the prospective PRAEGNANT registry (NCT02338167; n = 1,270) were used to calculate metabolic equivalent task (MET) minutes, which were subsequently categorized into low (n = 138), moderate (n = 995) or high IPAQ categories (n = 137). Cox regression analyses were used to evaluate the impact of IPAQ categories and its interaction with molecular subtypes on PFS and OS. Results Patient and tumor characteristics were equally distributed across IPAQ categories. HER2pos, HRpos and TNBC were present in 23.1%, 65.7% and 11.2% of patients, respectively. IPAQ scores did not have an impact on PFS and OS in addition to established prognostic factors, either overall or in particular molecular subtypes (PFS: p = 0.33 and OS: p = 0.08, likelihood ratio test). Exploratory analyses showed higher overall survival rates for high IPAQ categories compared to low/moderate IPAQ categories in luminal B-like breast cancer. Conclusions Self-reported physical activity using the IPAQ questionnaire did not significantly affect PFS or OS in patients suffering from metastatic breast cancer. Nevertheless, some hypothesis-generating differences between molecular subtypes could be observed, which may be interesting to evaluate further.

Keywords